Roivant Sciences Ltd. (ROIV) · Oct 21, 2026 · Other events

Roivant uveitis trial beats the bar across every endpoint

Above the bar — Primary endpoint met in both trials; all key secondary endpoints statistically significant

Roivant’s Phase 3 brepocitinib earnings-free clinical update delivered broad uveitis trial success, supporting a potential second LISRAYA indication.

Roivant is moving from a cash-rich development platform into its first commercial phase, with LISRAYA already approved for dermatomyositis and brepocitinib being expanded into additional immune-mediated diseases. The company had already told investors that NIU data were expected in the second half of 2026, so the timing was anticipated; the clinical strength was not.

The trial result clears the key clinical bar decisively. Brepocitinib met the primary endpoint in both identical Phase 3 studies and also produced statistically significant results on every key secondary endpoint. 〔0〕

Measure at Week 48CLARITY-1 brepocitinib vs placeboCLARITY-2 brepocitinib vs placebo
Hazard ratio for treatment failure0.27 vs placebo (95% CI 0.17–0.43)0.22 vs placebo (95% CI 0.14–0.34)
Cumulative treatment failure35.4% vs 78.7%32.4% vs 77.8%
Steroid-free quiescence in both eyes58.8% vs 19.8%64.4% vs 19.4%
Macular-edema resolution among affected eyes40.4% vs 2.1%42.6% vs 7.0%
≥5-point visual-function improvement36.4% vs 13.7%40.4% vs 14.1%

The breadth matters more than any single p-value. The drug showed disease control, steroid-sparing benefit, improvement in retinal leakage, macular-edema resolution and patient-reported visual function across two studies and several disease subgroups. Pooled steroid-free quiescence was 62% versus 20% for placebo, while median time to treatment failure exceeded 48 weeks versus roughly 12 weeks on placebo. 〔1〕

This advances brepocitinib from a single-product launch into a broader franchise opportunity. LISRAYA is now commercially available for dermatomyositis, and NIU could become the next indication for the same medicine rather than a separate pipeline bet. The filing’s comparison with existing therapies is company-framed, so the durable conclusion is not that superiority is proven, but that the data give Roivant a credible basis to pursue a differentiated systemic, steroid-free NIU label.

Safety does not offset the efficacy signal, but it also does not remove the remaining regulatory step. Only 3% of participants discontinued because of adverse events and no new safety signals were reported. 〔2〕 The next value-creating milestone is the planned supplemental New Drug Application in the first half of 2027, not immediate revenue from NIU.

Bottom line: This is a meaningful clinical upgrade to Roivant’s brepocitinib story: an anticipated readout, but materially better and broader than a routine positive result. It supports a potential second commercial indication while leaving approval and launch execution still ahead.

What to watch next

NIU sNDA filing, first half of 2027

Original filing on SEC EDGAR

More Roivant Sciences Ltd. news

Roivant uveitis trial beats the bar across every endpoint | ROIV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.